Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives $21.25 Consensus Target Price from Brokerages

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) has been assigned an average rating of “Buy” from the six ratings firms that are covering the firm, Marketbeat reports. Six analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokers that have covered the stock in the last year is $21.00.

Several research firms recently weighed in on ARTV. HC Wainwright began coverage on Artiva Biotherapeutics in a report on Monday. They issued a “buy” rating and a $20.00 target price for the company. Needham & Company LLC restated a “buy” rating and issued a $23.00 price objective on shares of Artiva Biotherapeutics in a research note on Wednesday, November 13th.

Artiva Biotherapeutics Price Performance

ARTV stock opened at $10.08 on Monday. Artiva Biotherapeutics has a 1 year low of $9.68 and a 1 year high of $17.31. The firm has a fifty day simple moving average of $11.37.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.92) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.24). Equities analysts forecast that Artiva Biotherapeutics will post -4.68 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets acquired a new stake in shares of Artiva Biotherapeutics in the third quarter worth $42,000. MetLife Investment Management LLC bought a new stake in Artiva Biotherapeutics in the 3rd quarter valued at $135,000. JPMorgan Chase & Co. acquired a new stake in Artiva Biotherapeutics in the 3rd quarter worth $166,000. Barclays PLC acquired a new stake in Artiva Biotherapeutics in the 3rd quarter worth $304,000. Finally, Charles Schwab Investment Management Inc. bought a new position in shares of Artiva Biotherapeutics during the 3rd quarter worth about $623,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.